Literature DB >> 19443972

Intravenous immunoglobulin therapy for autoantibody-positive cerebellar ataxia.

Kazunori Nanri1, Mitsunori Okita, Masafumi Takeguchi, Takeshi Taguchi, Tomoko Ishiko, Hirohiko Saito, Takao Otsuka, Hiroshi Mitoma, Kiyoshi Koizumi.   

Abstract

OBJECTIVE: It has been reported that autoimmune cerebellar ataxias, such as anti-glutamic acid decarboxylase (GAD)-antibody-positive cerebellar ataxia and gluten ataxia, are treatable. Here, we examined the therapeutic efficacy of intravenous immunoglobulin (IVIg) on autoantibody-positive cerebellar ataxia. PATIENTS AND METHODS: IVIg therapy was administered in seven autoantibody-positive cerebellar ataxia patients. Therapeutic efficacy was examined in terms of its effects on clinical symptoms and changes in brain perfusion using single photon emission computed tomography (SPECT).
RESULTS: Treatment was effective in four cerebellar cortical atrophy patients (two anti-GAD antibody-positive and two anti-gliadin antibody-positive) and in one anti-thyroid antibody-positive spinocerebellar ataxia type 3 (SCA3) patient, but not in two multiple system atrophy (MSA) patients. All four IVIg effective patients who underwent SPECT showed apparent increases in cerebellar perfusion.
CONCLUSION: If cerebellar ataxia with an autoimmune mechanism is suspected and radiological findings do not reveal MSA, it is worth considering immunotherapy including IVIg.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19443972     DOI: 10.2169/internalmedicine.48.1802

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  19 in total

1.  Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations.

Authors:  L M Patrias; A C Klaver; M P Coffey; D A Loeffler
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

Review 2.  Ataxia.

Authors:  Umar Akbar; Tetsuo Ashizawa
Journal:  Neurol Clin       Date:  2015-02       Impact factor: 3.806

3.  Consensus paper: radiological biomarkers of cerebellar diseases.

Authors:  Leonardo Baldarçara; Stuart Currie; M Hadjivassiliou; Nigel Hoggard; Allison Jack; Andrea P Jackowski; Mario Mascalchi; Cecilia Parazzini; Kathrin Reetz; Andrea Righini; Jörg B Schulz; Alessandra Vella; Sara Jane Webb; Christophe Habas
Journal:  Cerebellum       Date:  2015-04       Impact factor: 3.847

4.  Anti-GAD Antibody, Seizures, Cerebellar Ataxias and Vitiligo: A Diagnostic Challenge.

Authors:  Hazael Flores-Cantu; Carlos R Camara-Lemarroy; Hector J Calderon-Hernandez; Maria A Zapata-Rivera; Jesus Z Villareal-Perez; Hector J Villareal-Velazquez
Journal:  Cerebellum       Date:  2015-06       Impact factor: 3.847

5.  Multiple system atrophy: current and future approaches to management.

Authors:  Olivier Flabeau; Wassilios G Meissner; François Tison
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

6.  Animal models of human cerebellar ataxias: a cornerstone for the therapies of the twenty-first century.

Authors:  Mario Manto; Daniele Marmolino
Journal:  Cerebellum       Date:  2009-09       Impact factor: 3.847

7.  Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy.

Authors:  Helena Ariño; Nuria Gresa-Arribas; Yolanda Blanco; Eugenia Martínez-Hernández; Lidia Sabater; Mar Petit-Pedrol; Idoia Rouco; Luis Bataller; Josep O Dalmau; Albert Saiz; Francesc Graus
Journal:  JAMA Neurol       Date:  2014-08       Impact factor: 18.302

8.  Anti transglutaminase antibodies cause ataxia in mice.

Authors:  Sabrina Boscolo; Andrea Lorenzon; Daniele Sblattero; Fiorella Florian; Marco Stebel; Roberto Marzari; Tarcisio Not; Daniel Aeschlimann; Alessandro Ventura; Marios Hadjivassiliou; Enrico Tongiorgi
Journal:  PLoS One       Date:  2010-03-15       Impact factor: 3.240

9.  Gluten ataxia in Japan.

Authors:  Kazunori Nanri; Hiroshi Mitoma; Masafumi Ihara; Nobuyuki Tanaka; Takeshi Taguchi; Masafumi Takeguchi; Tomoko Ishiko; Hidehiro Mizusawa
Journal:  Cerebellum       Date:  2014-10       Impact factor: 3.847

10.  Low-titer anti-GAD-antibody-positive cerebellar ataxia.

Authors:  Kazunori Nanri; Hisayoshi Niwa; Hiroshi Mitoma; Asako Takei; Junko Ikeda; Toshihide Harada; Mitsunori Okita; Masafumi Takeguchi; Takeshi Taguchi; Hidehiro Mizusawa
Journal:  Cerebellum       Date:  2013-04       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.